Menveo + Twinrix

This entry refers to the concomitant administration of two separate vaccines: Menveo (MenACWY-CRM) and Twinrix. Menveo is a quadrivalent meningococcal conjugate vaccine developed by Novartis Vaccines (now GSK) that contains capsular polysaccharides from *Neisseria meningitidis* serogroups A, C, W, and Y, each conjugated to a CRM197 carrier protein. It is indicated for active immunization to prevent invasive meningococcal disease. Twinrix is a combined vaccine containing inactivated hepatitis A virus and recombinant hepatitis B surface antigen (HBsAg), developed by GSK. A Phase 3b clinical study (NCT00971308) evaluated the safety and immunogenicity of administering these two vaccines together in healthy adults, a regimen particularly relevant for travelers to endemic areas who require protection against both meningococcal disease and viral hepatitis.

Brand names

Twinrix

Other names

Novartis meningococcal ACWY conjugate vaccineCombined inactivated hepatitis A and recombinant hepatitis B vaccine